Lowest Price Guaranteed
From USD
2,999
Published
March 2019
Pages
220
View Count
2344
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
.PNG) |
Alzheimer’s disease is both progressive and irreversible, moreover, the cause of the disease is not yet well understood. It is important to generate awareness about the disease among the general population and stay updated with the innovation and research engaged in this domain
-- Key Opinion Leader and Chief Medical Officer, Large-sized US based Company
Alzheimer’s disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction anddementia. Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US. It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer’s disease. During the same year, Alzheimer’s disease and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Considering that only a limited range of diagnosis, treatment and disease management solutions are presently available, this segment of the healthcare industry is presently faced with a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options that have the capability to slow the progression of the condition.
Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimer’s disease, only six drugs have been approved since 1996 for treatment. The rate of failure of drugs being developed for treating Alzheimer’s disease is alarming (~99.6%) and is even higher than that reported for cancer (~81%). Most of the existing therapeutic options have proven inadequate in arresting the progression of the disease and long term management of associated symptoms. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease modifyinginterventions and drug / therapy candidates that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital and other strategic investors. In the coming years, the market is anticipated to grow at a significant pace as more novel solutions clear clinical evaluation and get commercialized.
The “Alzheimer’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Alzheimer’s disease. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in detail in the document.
Figure 1.1 Alzheimer’s Disease: Scope and Competitive Insights
Amongst other elements, the report includes:
The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from secondary sources. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company name):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the Alzheimer’s disease market in the long term.
Chapter 3 provides a brief introduction to Alzheimer’s disease, and its associated symptoms. It also features a detailed discussion on the causes of the condition (based on various existing hypotheses), stages of disease progression, factors influencing the onset and progression of the disease, and the different pharmacological and non-pharmacological interventions that are presently indicated for the treatment of this condition. The chapter includes a discussion on the epidemiology of the disease and highlights the diverse initiatives / programs led by the National Institutes of Health (NIH) to support scientific discovery and help in disease management.
Chapter 4 includes information on over 200 molecules that are currently approved / under development for the treatment of Alzheimer’s disease. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), target stage of disease (early, mid or late stage), type of therapy (monotherapy or combination therapy), path to clinics (dedicated, repositioned or repurposed), and mechanism of action and route of administration of the drugs being developed for the treatment of the disease. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength. In addition, it presents certain key insights derived from the study, which includes a representation highlighting the distribution of the marketed and pipeline molecules based on various mechanisms of action. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of the clinical drug candidates across type of therapy, path to clinic and stage of development. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.
Chapter 5 highlights the key unmet needs associated with the management and treatment of Alzheimer’s disease. The chapter provides detailed analysis of the various challenges and areas of concern, which wereidentified from views expressed by patients / experts across different platforms, such as social media posts, recent scientific publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful word cloud analysis, summarizing the opinions expressed across public online portals.
Chapter 6 features a detailed assessment of over 70 discontinued drugs, providing information on the reason(s) for discontinuation, year of discontinuation, mechanism of action of the terminated drugs, phase of discontinuation and the target stage of disease. In addition, the chapter presents over 180 terminated clinical trials highlighting the year of termination and the key geographies where these trials were being conducted.
Chapter 7 provides a detailed analysis of close to 300 research articles related to Alzheimer’s disease, published till 2018. The analysis takes into consideration several parameters, such as biological targets being studied, study type (review article, research article, meta-analysis and clinical trials), year of publication, and the most popular journals within this domain.
Chapter 8 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial agreements) that have been established till 2019 (February).
Chapter 9 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till January 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.
Chapter 10 provides information on the various non-pharmacological interventions, such as cognitive / emotion-oriented therapies, sensory simulation therapies and other psychological interventions, which aim to delay the loss of mental capability and help the patients retain their identity and functional autonomy. The chapter also presents a list of companies that offer such solutions, describing the devices / products and their mechanisms of action / working principles. In addition, the chapter include a list of novel diagnostic techniques, which claim to be capable of assisting in timely diagnosis.
Chapter 11 summarizes the entire report. It presents a list of key takeaways and our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of therapeutic interventions in disease area.
Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)) and Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1.Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Alzheimer’s Disease
3.1.1. Epidemiology
3.1.2. Symptoms of the Disease
3.1.3. Causes of Alzheimer’s Disease
3.1.4. Stages of Alzheimer’s Disease
3.2. Alzheimer’s Disease: Initiatives And Programs by The National Institutes of Health
3.3. Management of Alzheimer’s Disease
3.3.1. Interventional Therapies
3.3.2. Non-Interventional Therapies
3.3.2.1. Behavior Management
3.3.2.2. Lifestyle Management
3.3.2.3. Creating a Safe and a Supportive Environment
3.4. Future Perspectives
4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS
4.1. Chapter Overview
4.2. Alzheimer’s Disease Therapy: Marketed and Development Pipeline
4.3. Alzheimer’s Disease Therapy: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Target Stage of Disease
4.3.4. Analysis by Type of Treatment
4.3.5. Analysis by Mechanism of Action
4.3.6. Analysis by Route of Administration
4.3.7. Analysis by Dosing Frequency
4.3.8. Analysis by Type of Therapy
4.3.9. Analysis by Path to Clinic
4.3.10. Grid Analysis: Distribution by Type of Therapy, Phase of Development and Path to Clinic
4.4. Alzheimer’s Disease Therapy: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developers
4.4.4. Grid Analysis: Distribution by Location, Size of Industry Players and Mechanism of Action of Pipeline Drugs
4.4.5. Analysis by Geography
5. ALZHEIMER’S DISEASE: UNMET NEEDS ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs Associated with Alzheimer’s Disease
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights
5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights
5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights
5.2.4. Expert Opinions
5.2.4.1. Rudy Tanzi, Professor of Neurology, Harvard University
5.2.4.2. Samuel Cohen, CEO and Co-Founder, Wren Therapeutics
5.2.4.3. Brandon Brock, Chiropractic Neurologist / Staff Clinician, Cerebrum Health Centers
5.2.4.4. Ronald C Petersen, Director, Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging
5.2.4.5. Neal Barnard, Founding President, The Physicians Committee for Responsible Medicine
5.2.4.6. Peter V Rabins, Proffesor, Johns Hopkins University School of Medicines
5.2.4.7. Joe Dispenza, International Lecturer / Professor, Quantum University
5.2.4.8. Freda Lewis-Hall, Chief Medical Officer, Pfizer
5.2.4.9. Dheeraj Roy, Professor, The Broad Institute of MIT and Harvard
5.2.4.10. Joseph Jebelli, Neuroscientist and Author
5.2.5. Summary of Key Unmet Needs associated with Alzheimer’s Disease
6. CASE STUDY: TERMINATED DRUGS
6.1. Chapter Overview
6.2. Alzheimer’s Disease Therapy: List of Terminated Drugs
6.2.1. Distribution of Drugs by Year of Discontinuation
6.2.2. Distribution by Phase of Discontinuation
6.2.3. Distribution by Mechanism of Action
6.2.4. Distribution by Terminated Drugs by Type of Indication
6.2.5. Distribution by Reason for Termination
6.2.6. Distribution by Affiliated Stakeholders
6.3. Alzheimer’s Disease: List of Terminated Clinical Trials
6.3.1. Distribution of Study Start Year and Year of Termination of Clinical Trials
6.3.2. Distribution on Trial Region(s)
6.4. Concluding Remarks
7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Alzheimer’s Disease: List of Publications
7.3.1. Analysis by Type of Study
7.3.2. Analysis by Study Objective
7.3.3. Analysis by Type of Therapeutic Targets
7.3.4. Key Journals
8. PARTNERSHIP AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Alzheimer’s Disease: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partnership and Focus Area of the Agreement
8.3.4. Analysis by Type of Partnership and Type of Molecule
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.7. Interncontinental and Intracontinental Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested Across Different Types of Molecules
9.3.5. Analysis by Amount Invested Value Across Different Types of Mechanism of Action
9.3.6. Regional Analysis by Amount Invested
9.3.7. Most Active Players
9.3.8. Most Active Investors
9.4. Concluding Remarks
10. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS
10.1. Chapter Overview
10.2. Non-Pharmacological Interventions for Alzheimer’s Disease
10.2.1. Cognition / Emotion-Oriented Interventions
10.2.1.1. Reminiscence Therapy
10.2.1.2. Simulated Presence Therapy
10.2.2. Sensory Stimulation-based Interventions
10.2.2.1. Virtual Reality
10.2.2.2. Music Therapy
10.2.2.3. Light Therapy
10.2.2.4. Aromatherapy
10.2.2.5. Reflexology
10.2.3. Other Psychosocial Interventions
10.2.3.1. Animal-Assisted Therapy
10.3. Alzheimer’s Disease Therapy: List of Companies Offering Non-Pharmacological Interventions and Diagnostic Tests
11. ALZHEIMER’S DISEASE THERAPY: CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Cognition Therapeutics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Kenneth Moch, President and Chief Executive Officer
12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Global Statistics of Dementia: 2015 and 2030 (USD Million)
Figure 3.2 Alzheimer’s Disease: Signs and Symptoms
Figure 3.3 Alzheimer’s Disease: Normal Brain versus Diseased Brain
Figure 3.4 Alzheimer’s Disease: Stages of Disease Progression
Figure 3.5 Alzheimer’s Disease: Dietary Supplements for Disease Management
Figure 3.6 Alzheimer’s Disease: Important Steps toward Creating a Supportive Environment
Figure 4.1 Alzheimer’s Disease Therapy: Distribution by Phase of Development
Figure 4.10 Grid Analysis: Distribution of Pipeline Therapies by Phase of Development, Type of Therapy and Path to Clinic
Figure 4.11 Alzheimer’s Disease: Distribution by Year of Establishment of Developer
Figure 4.12 Alzheimer’s Disease: Distribution by Size and Location of Developer
Figure 4.13 Pipeline Analysis: Leading Players
Figure 4.14 Grid Analysis: Distribution by Location, Size and Mechanism of Action of Pipeline Drugs
Figure 4.15 Geographical Landscape
Figure 5.1 Unmet Needs Analysis: Overview of Methodology
Figure 5.2 Unmet Needs in Alzheimer’s Disease: Word Cloud Analysis of Data from Patient Blog
Figure 5.3 Unmet Needs in Alzheimer’s Disease: Needs Highlighted across Published Literature
Figure 5.4 Unmet Needs in Alzheimer’s Disease: Word Cloud Analysis of Data from Social Media
Figure 5.5 Unmet Needs in Alzheimer’s Disease: Summary
Figure 6.1 Terminated Drugs: Cumulative Distribution of Drugs by Year of Discontinuation
Figure 6.2 Terminated Drugs: Distribution by Phase of Discontinuation
Figure 6.3 Terminated Drugs: Distribution by Mechanism of Action
Figure 6.4 Terminated Drugs: Distribution of Terminated Drugs by Type of Indication
Figure 6.5 Terminated Drugs: Distribution by Affiliated Stakeholders
Figure 6.6 Terminated Drugs: Distribution by Reason for Termination
Figure 6.7 Terminated Drugs: Word Cloud on Reason for Termination
Figure 6.8 Terminated Drugs: Distribution by Key Players
Figure 6.9 Terminated Drugs: Distribution by Study Start Year and Year of Termination of the Clinical Trials for Alzheimer’s Disease
Figure 6.10 Terminated Drugs: Regional Distribution of Failed Clinical Trials
Figure 6.11 Bubble Analysis: Distribution by Year of Termination, Reason of Termination and Phase of Development
Figure 6.12 Terminated Drugs: Precaution for Evaluating New Clinical Trials
Figure 7.1 Publications: Year-wise Trend, 2010-2018
Figure 7.2 Publications: Distribution by Type of Study
Figure 7.3 Publications: Distribution by Study Objective
Figure 7.4 Publications: Word Cloud on Therapeutic Targets
Figure 7.5 Publications: Most Popular Journals
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Molecule and Type of Partnership
Figure 8.6 Partnerships and Collaborations: Most Active Players
Figure 8.7 Partnerships and Collaborations: Activity of Big Pharmaceutical Companies
Figure 8.8 Partnership and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1 Distribution by Type of Funding and Year of Establishment, 2013-2019
Figure 9.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2013-2019
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding and Year, 2013-2019
Figure 9.4 Funding and Investment Analysis: Cumulative Amount Invested, 2013-2019 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2013-2019
Figure 9.6 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2013-2019 (USD Million)
Figure 9.7 Funding and Investment Analysis: Summary of Investments, 2013-2019 (USD Million)
Figure 9.8 Funding and Investments: Most Funded Molecules by Number of Instances and Amount Invested, 2013-2019 (USD Million)
Figure 9.9 Funding and Investment Analysis: Popular Mechanisms of Action 2013-2019 (USD Million)
Figure 9.10 Funding and Investment Analysis: Distribution by Geography
Figure 9.11 Funding and Investment Analysis: Most Active Players, 2013-2019 (USD Million)
Figure 9.12 Funding and Investment Analysis: Most Active Investors
Figure 9.13 Funding and Investment Summary, 2013-2019 (USD Million)
Figure 10.1 Alzheimer’s Disease: Non-Pharmacological Interventions
Figure 10.2 Alzheimer’s Disease: Different Forms of Music Therapy
Table 4.1 Alzheimer’s Disease Therapy: Marketed and Development Pipeline
Table 4.2 Alzheimer’s Disease Therapy: Information on Type of Therapy and Path to Clinic
Table 4.3 Alzheimer’s Disease Therapy: Developer Overview
Table 4.4 Alzheimer’s Disease Therapy: Initiatives by Large Pharma Players
Table 6.1 Alzheimer’s Disease: Pipeline of Terminated Drugs
Table 6.2 Alzheimer’s Disease: List of Terminated Clinical Trials
Table 7.1 Alzheimer’s Disease: List of Publications, 2017-2018
Table 8.1 Alzheimer’s Disease: Partnerships and Collaborations, 2013-2019
Table 9.1 Alzheimer’s Disease Market: Funding and Investments, 2013-2019
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Alzheimer’s Disease: List of Companies Providing Non-Pharmacological Interventions and Diagnostic Tests
Table 11.1 Alzheimer’s Disease: Concluding Remarks
Table 12.1 Cognition Therapeutics: Key Highlights
Table 12.2 ICB International: Key Highlights
Table 13.1 Alzheimer’s Disease Therapy: Distribution by Phase of Development
Table 13.2 Alzheimer’s Disease Therapy: Distribution by Type of Molecule
Table 13.3 Alzheimer’s Disease Therapy: Distribution by Target Stage of Disease
Table 13.4 Alzheimer’s Disease Therapy: Distribution by Type of Treatment
Table 13.5 Alzheimer’s Disease Therapy: Distribution by Type of Mechanism of Action
Table 13.6 Alzheimer’s Disease Therapy: Distribution by Route of Administration
Table 13.7 Alzheimer’s Disease Therapy: Distribution by Dosing Frequency
Table 13.8 Alzheimer’s Disease Therapy: Distribution by Type of Therapy
Table 13.9 Alzheimer’s Disease Therapy: Distribution by Path to Clinic
Table 13.10 Drug Developers for Alzheimer’s Disease: Distribution by Year of Establishment of Developer
Table 13.11 Alzheimer’s Disease Therapy: Distribution by Size and Location of Developer
Table 13.12 Pipeline Analysis: Leading Players
Table 13.13 Unmet Needs in Alzheimer’s Disease: Needs Highlighted Across Published Literature
Table 13.14 Terminated Drugs: Cumulative Distribution of Drugs by Year of Discontinuation
Table 13.15 Terminated Drugs: Distribution by Phase of Discontinuation
Table 13.16 Terminated Drugs: Distribution by Mechanism of Action
Table 13.17 Terminated Drugs: Distribution by Target Stage of Disease
Table 13.18 Terminated Drugs: Distribution by Reason for Termination
Table 13.19 Terminated Drugs: Distribution by Key Players
Table 13.20 Terminated Drugs: Distribution by Study Start Year and Year of Termination of the Clinical Trials
Table 13.21 Publications: Year-wise Trend, 2010-2018
Table 13.22 Publications: Distribution by Type of Study
Table 13.23 Publications: Distribution by Study Objective
Table 13.24 Publications: Most Popular Journals
Table 13.25 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2018
Table 13.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.27 Partnerships and Collaborations: Distribution of Type of Partnership, Pre-2016 and 2016-2019
Table 13.28 Partnerships and Collaborations: Most Active Players
Table 13.29 Partnerships and Collaborations: Regional Distribution
Table 13.30 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, 2013-2019
Table 13.31 Funding and Investments: Cumulative Number of Instances, 2013-2019
Table 13.32 Funding and Investments: Distribution by Type of Funding and Year, 2013-2019
Table 13.33 Funding and Investments: Cumulative Amount Invested, 2013-2019 (USD Million)
Table 13.34 Funding and Investments: Distribution by Type of Funding, 2013-2019 (Number of Instances)
Table 13.35 Funding and Investments: Distribution of Total Amount Invested by Type of Funding, 2013-2019 (USD Million)
Table 13.36 Funding and Investments: Popular Mechanisms of Action 2013-2019 (USD Million)
Table 13.37 Funding and Investments: Most Active Players, 2013-2019 (USD Million)
Table 13.38 Funding and Investments: Most Active Investors
The following companies and organizations have been mentioned in the report:
Discounts available for multiple report purchases
sales@rootsanalysis.net
.png)
.jpg)
.png)
.png)
.jpg)
.jpg)
.jpg)
